Evidence map›Paper›PMID 35000485›Full record

ArticleThe Journal of international medical research2022

Guanidinoacetate-creatine in secondary progressive multiple sclerosis: a case report.

Sergej M Ostojic, Jelena Ostojic, Dragana Zanini, Tatjana Jezdimirovic, Valdemar Stajer

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of international medical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 3 countries.

Sergej M OstojicFSPE Applied Bioenergetics Lab, 84981University of Novi Sad, University of Novi Sad, Novi Sad, Serbia.ORCID https://orcid.org/0000-0002-7270-2541
Jelena OstojicFaculty of Medicine, 84981University of Novi Sad, University of Novi Sad, Novi Sad, Serbia.
Dragana ZaniniFSPE Applied Bioenergetics Lab, 84981University of Novi Sad, University of Novi Sad, Novi Sad, Serbia.
Tatjana JezdimirovicFSPE Applied Bioenergetics Lab, 84981University of Novi Sad, University of Novi Sad, Novi Sad, Serbia.
Valdemar StajerFSPE Applied Bioenergetics Lab, 84981University of Novi Sad, University of Novi Sad, Novi Sad, Serbia.
University of Novi Sad · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute secondary progressive multiple sclerosis (SPMS) is characterized by escalating neurological disability, with limited disease-modifying therapeutic options. A 48-year-old woman with acute SPMS being treated with interferon beta-1a and oral corticosteroids presented as a clinical outpatient with no disease-modifying effects after treatment. A decision was made to treat her with a combination of guanidinoacetate and creatine for 21 days. She had made clinical progress at follow-up, with the intensity of fatigue dropping from severe to mild. Magnetic resonance spectroscopy revealed increased brain choline, creatine, N-acetylaspartate, and glutathione. Patients with SPMS may benefit from guanidinoacetate-creatine treatment in terms of patient- and clinician-reported outcomes; this requires additional study.

Indexed as

Multiple SclerosisMultiple Sclerosis, Chronic ProgressiveCreatineFemaleGlycineHumansMagnetic Resonance SpectroscopyMiddle AgedCreatineGlycineglycocyaminebrain metabolismcase reportcreatineguanidinoacetic acidMultiple sclerosispatient outcome

Identifiers

PMID35000485
PMCPMC8753084
OpenAlexW4206118405

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.